Correct Capital Wealth Management Invests $644,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Correct Capital Wealth Management bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the first quarter, according to its most recent filing with the SEC. The fund bought 6,595 shares of the medical equipment provider's stock, valued at approximately $644,000.

Other hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its stake in Lantheus by 3.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider's stock valued at $1,162,000 after acquiring an additional 400 shares during the period. State of Alaska Department of Revenue raised its stake in Lantheus by 2.7% in the 1st quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider's stock valued at $794,000 after acquiring an additional 215 shares during the period. GAMMA Investing LLC raised its stake in Lantheus by 12,517.1% in the 1st quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider's stock valued at $12,536,000 after acquiring an additional 127,424 shares during the period. Pictet Asset Management Holding SA raised its stake in Lantheus by 12.1% in the 4th quarter. Pictet Asset Management Holding SA now owns 10,294 shares of the medical equipment provider's stock valued at $921,000 after acquiring an additional 1,113 shares during the period. Finally, Assenagon Asset Management S.A. raised its stake in Lantheus by 1,196.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider's stock valued at $32,817,000 after acquiring an additional 310,301 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.00% of the company's stock.

Lantheus Price Performance

Shares of LNTH traded down $2.52 during midday trading on Friday, hitting $81.31. 816,768 shares of the company traded hands, compared to its average volume of 975,278. The stock has a 50-day moving average of $80.26 and a 200-day moving average of $89.91. Lantheus Holdings, Inc. has a one year low of $73.11 and a one year high of $126.89. The firm has a market cap of $5.63 billion, a P/E ratio of 23.10 and a beta of 0.12. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The company had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. During the same quarter in the prior year, the company earned $1.69 earnings per share. The company's quarterly revenue was up .8% on a year-over-year basis. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on LNTH. Truist Financial lowered their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. B. Riley decreased their price target on Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. Finally, Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Lantheus has a consensus rating of "Buy" and an average price target of $131.20.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.